Ofloxacin induced hypersensitivity reaction

Hari Babu Ramineni, Pravallika Eluri, Kumudini Vipparla, Vidyadahara Suryadevara


Ofloxacin is a commonly used antimicrobial agent to combat various infections. The adverse profile of quinolones includes gastrointestinal symptoms, which are the most frequent, neuropsychiatric symptoms, hematologic abnormalities are less common. We report a rare case of ofloxacin induced hypersensitivity reaction in a 57 year old female patient with complaints of rashes over the axilla, upper limb and back, abdomen, thorax associated with exfoliation of skin all over the axilla associated with severe itching. Based on history and clinical examination patient was diagnosed as ofloxacin induced hypersensitivity reaction and was successfully treated with antihistamines and corticosteroids. Pharmacovigilance should be a part of patient care in order to reduce occurrence of adverse drug reaction and also encourage practitioners in reporting so as to gather more and more data regarding adverse drug reactions.


Ofloxacin, Hypersensitivity, Maculopapular, Antihistamines

Full Text:



Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis. 2007 Apr;44(7):977-80.

Kawahara, S. Chemotherapeutic agents under study. Nippon Rinsho. 1998 Dec;56(12):3096-9.

Young-Hee Nam, Jeong Eun Kim, Seung-Hyun Kim, Hyun Jung Jin, Eui-Kyung Hwang, Yoo Seob Shin, et al. immunologic evaluation of ofloxacin hypersensitivity. Allergy Asthma Immunol Res. 2012 Nov;4(6):367-9.

Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005 Jul;41(Suppl 2):S144-57.

De Sarro A, De Sarro G, De Sarro. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem. 2001 Mar;8(4):371-4.

Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M, et al. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2012 Apr;19(4):370-8.

Falagas ME, Matthaiou DK, Vardakas KZ, Vardakas M. Fluoroquinolones vs. beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2006 Dec;81(12):1553-66.

Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009;32(5):359-78.

Andriole VT. The future of the quinolones. Drugs. 1999;58(Suppl 2):1-5.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.

WHO. The use of the WHO-UMC system for standardised case causality assessment, 2014. Available at: http://www.WHO-UMC.org/graphics/4409.pdf. Accessed 22 October 2014.

Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26(2):123-9.